Optomed Oyj financials
Optomed Oyj
7437009IVYWGEE4S7B77 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €17.1M | €15.0M |
| Other income | €5.0K | €10.0K |
| Employee benefits expense | €9.9M | €8.9M |
| Operating profit (EBIT) | -€6.0M | -€6.0M |
| Net finance income / (cost) | -€676.0K | €441.0K |
| Finance costs | €1.3M | €776.0K |
| Profit before tax | -€6.7M | -€5.5M |
| Income tax expense | -€77.0K | -€66.0K |
| Profit for the year | -€6.6M | -€5.5M |
| — attributable to owners | -€6.6M | -€5.5M |
| Total comprehensive income | -€5.8M | -€5.8M |
| Per share | ||
| Basic EPS | €-0.34 | €-0.29 |
| Free cash flow / share | €-0.16 | €-0.10 |
| Cash flow statement | ||
| Cash generated from operations | -€2.4M | -€1.5M |
| Net cash from operating activities | -€2.5M | -€1.6M |
| Net cash from investing activities | -€2.4M | -€2.1M |
| Purchase of PP&E (capex) | €561.0K | €275.0K |
| Purchase of intangibles | €1.8M | €1.8M |
| Net cash from financing activities | €4.2M | €7.1M |
| Repayments of borrowings | €863.0K | €1.1M |
| Lease liability payments | €517.0K | €494.0K |
| Net change in cash | -€653.0K | €3.4M |
| Balance sheet | ||
| Total assets | €32.0M | €31.8M |
| Non-current assets | €16.2M | €16.1M |
| Property, plant & equipment | €894.0K | €652.0K |
| Right-of-use assets | €1.2M | €1.5M |
| Intangible assets & goodwill | €14.1M | €14.0M |
| Current assets | €15.8M | €15.7M |
| Inventories | €2.4M | €2.0M |
| Trade & other receivables | €2.8M | €2.4M |
| Cash & equivalents | €9.9M | €10.5M |
| Total equity | €24.0M | €23.6M |
| Non-current liabilities | €1.4M | €2.6M |
| Long-term borrowings | €0 | €790.0K |
| Lease liabilities (non-current) | €835.0K | €1.0M |
| Current liabilities | €6.6M | €5.6M |
| Short-term borrowings | €789.0K | €794.0K |
| Lease liabilities (current) | €442.0K | €495.0K |
| Deferred tax liabilities | €157.0K | €234.0K |
| Derived metrics | ||
| Free cash flow | -€3.0M | -€1.9M |
| Operating margin | -35.3% | -39.6% |
| Net margin | -38.8% | -36.2% |
| Return on equity | -27.6% | -23.1% |
| Cash conversion ratio | 0.37× | 0.29× |
| Capex coverage | -4.42× | -5.80× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€492.0K | €901.0K |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€483.0K | -€335.0K |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €2.5M | €2.5M |
| Adjustments For Finance Income Cost | -€430.0K | €466.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | €1.7M | €688.0K |
| Cash Flows From Used In Operations Before Changes In Working Capital | -€3.2M | -€2.8M |
| Comprehensive Income Attributable To Owners of Parent | -€5.8M | -€5.8M |
| Deferred Tax Assets | €13.0K | €12.0K |
| Depreciation Amortisation and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €2.5M | €2.5M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €95.0K | -€19.0K |
| Equity and Liabilities | €32.0M | €31.8M |
| Finance Costs Paid Classified As Operating Activities | €112.0K | €121.0K |
| Finance Income | €580.0K | €1.2M |
| Increase Decrease Through Exercise of Options | €549.0K | €1.7M |
| Increase Decrease Through Sharebased Payment Transactions | €51.0K | €43.0K |
| Increase Decrease Through Transactions With Owners | €6.2M | €9.1M |
| Intangible Assets Under Development | €8.7M | €8.3M |
| Interest Paid Classified As Operating Activities | €54.0K | €115.0K |
| Interest Received Classified As Operating Activities | €115.0K | €151.0K |
| Issue of Equity | €5.6M | €7.3M |
| Issued Capital | €80.0K | €80.0K |
| Liabilities | €8.0M | €8.1M |
| Other Adjustments For Noncash Items | €537.0K | €653.0K |
| Other Comprehensive Income | €855.0K | -€329.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | €855.0K | -€329.0K |
| Other Current Payables | €3.9M | €3.2M |
| Other Current Receivables | €718.0K | €857.0K |
| Other Expense By Nature | €4.5M | €4.2M |
| Other Intangible Assets | €365.0K | €370.0K |
| Payments For Share Issue Costs | €419.0K | €553.0K |
| Proceeds From Issuing Shares | €6.0M | €9.2M |
| Reserve of Exchange Differences On Translation | €861.0K | €6.0K |
| Retained Earnings Excluding Profit Loss For Reporting Period | -€36.0M | -€31.1M |
| Retained Earnings Profit Loss For Reporting Period | -€6.6M | -€5.5M |
| Share Premium | €504.0K | €504.0K |
| Trade and Other Current Payables To Trade Suppliers | €1.2M | €891.0K |
Every line item above is a fact tagged in Optomed Oyj's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.